Roche Diagnostics purchased assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow. These assets include the NimbleGen Hybridization Systems (both 4- and 12-bay models) and array accessories covering all mixers designed for the Roche NimbleGen high-density microarray portfolio.


With the purchase of these assets, Roche Diagnostics will transfer the manufacturing capabilities for the above products to an in-house manufacturing facility. “The acquired products are integral to the high-quality data the NimbleGen array workflow provides researchers worldwide,” points out Andreas Görtz, vp of marketing at Roche NimbleGen.

Previous articleAbbott’s $450M Acquisition Offer for Facet Trumps Biogen Idec’s
Next articleIpsen Licenses Preclinical MSH and Ghrelin Agonist Programs to Rhythm Pharmaceuticals